US20200179310A1 - Compositions comprising salbutamol sulphate - Google Patents
Compositions comprising salbutamol sulphate Download PDFInfo
- Publication number
- US20200179310A1 US20200179310A1 US16/782,143 US202016782143A US2020179310A1 US 20200179310 A1 US20200179310 A1 US 20200179310A1 US 202016782143 A US202016782143 A US 202016782143A US 2020179310 A1 US2020179310 A1 US 2020179310A1
- Authority
- US
- United States
- Prior art keywords
- propellant
- pharmaceutical composition
- component
- surfactant
- difluoroethane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 239000003380 propellant Substances 0.000 claims abstract description 79
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 66
- 239000004094 surface-active agent Substances 0.000 claims abstract description 59
- 239000003814 drug Substances 0.000 claims abstract description 57
- 229940079593 drug Drugs 0.000 claims abstract description 56
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 claims abstract description 43
- 229940071648 metered dose inhaler Drugs 0.000 claims abstract description 30
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 26
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 239000002245 particle Substances 0.000 claims description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 3
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 3
- 239000004147 Sorbitan trioleate Substances 0.000 claims description 3
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims description 3
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 3
- 229940093471 ethyl oleate Drugs 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 239000001593 sorbitan monooleate Substances 0.000 claims description 3
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 3
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 3
- 235000019337 sorbitan trioleate Nutrition 0.000 claims description 3
- 229960000391 sorbitan trioleate Drugs 0.000 claims description 3
- 229940074928 isopropyl myristate Drugs 0.000 claims 2
- 229940068917 polyethylene glycols Drugs 0.000 claims 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 abstract description 12
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 abstract description 12
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 abstract description 12
- 239000005642 Oleic acid Substances 0.000 abstract description 12
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 abstract description 12
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 abstract description 12
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 12
- 239000000725 suspension Substances 0.000 description 10
- 239000000443 aerosol Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 5
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000023504 respiratory system disease Diseases 0.000 description 4
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 4
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- RWRIWBAIICGTTQ-UHFFFAOYSA-N difluoromethane Chemical compound FCF RWRIWBAIICGTTQ-UHFFFAOYSA-N 0.000 description 3
- 239000013583 drug formulation Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 229940029284 trichlorofluoromethane Drugs 0.000 description 3
- CDOOAUSHHFGWSA-OWOJBTEDSA-N (e)-1,3,3,3-tetrafluoroprop-1-ene Chemical compound F\C=C\C(F)(F)F CDOOAUSHHFGWSA-OWOJBTEDSA-N 0.000 description 2
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 2
- FXRLMCRCYDHQFW-UHFFFAOYSA-N 2,3,3,3-tetrafluoropropene Chemical compound FC(=C)C(F)(F)F FXRLMCRCYDHQFW-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000004378 air conditioning Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 239000003507 refrigerant Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 239000004446 fluoropolymer coating Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Definitions
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising salbutamol sulphate, a propellant and a surfactant.
- the composition is suitable for delivering the salbutamol sulphate from a pressurised aerosol container using a metered dose inhaler (MDI).
- MDI metered dose inhaler
- MDIs are the most significant type of inhalation drug delivery system and are well known to those skilled in the art. They are designed to deliver, on demand, a discrete and accurate amount of a drug to the respiratory tract of a patient using a liquefied propellant in which the drug is dissolved, suspended or dispersed.
- the design and operation of MDIs is described in many standard textbooks and in the patent literature. They all comprise a pressurised container that holds the drug formulation, a nozzle and a valve assembly that is capable of dispensing a controlled quantity of the drug through the nozzle when it is activated. All of these components are typically located in a housing that is equipped with a mouth piece.
- the drug formulation will comprise a propellant, in which the drug is dissolved, suspended or dispersed, and may contain other materials such as polar excipients, surfactants and preservatives.
- a propellant In order for a propellant to function satisfactorily in MDIs, it needs to have a number of properties. These include an appropriate boiling point and vapour pressure so that it can be liquefied in a closed container at room temperature but develop a high enough pressure when the MDI is activated to deliver the drug as an atomised formulation even at low ambient temperatures. Further, the propellant should be of low acute and chronic toxicity and have a high cardiac sensitisation threshold. It should have a high degree of chemical stability in contact with the drug, the container and the metallic and non-metallic components of the MDI device, and have a low propensity to extract low molecular weight substances from any elastomeric materials in the MDI device.
- the propellant should also be capable of maintaining the drug in a homogeneous solution, in a stable suspension or in a stable dispersion for a sufficient time to permit reproducible delivery of the drug in use.
- the density of the liquid propellant is desirably similar to that of the solid drug in order to avoid rapid sinking or floating of the drug particles in the liquid.
- the propellant should not present a significant flammability risk to the patient in use. In particular, it should form a non-flammable or low flammability mixture when mixed with air in the respiratory tract.
- Dichlorodifluoromethane (R-12) possesses a suitable combination of properties and was for many years the most widely used MDI propellant, often blended with trichlorofluoromethane (R-11). Due to international concern that fully and partially halogenated chlorofluorocarbons (CFCs), such as dichlorodifluoromethane and trichlorofluoromethane, were damaging the earth's protective ozone layer, many countries entered into an agreement, the Montreal Protocol, stipulating that their manufacture and use should be severely restricted and eventually phased out completely. Dichlorodifluoromethane and trichlorofluoromethane were phased out for refrigeration use in the 1990's, but are still used in small quantities in the MDI sector as a result of an essential use exemption in the Montreal Protocol.
- CFCs chlorofluorocarbons
- R-134a 1,1,1,2-tetrafluoroethane
- R-12 1,1,1,2,3,3,3-heptafluoropropane
- R-227ea 1,1,1,2,3,3,3-heptafluoropropane
- R-114 dichlorotetrafluoroethane
- R-134a and R-227ea have low ozone depletion potentials (ODPs), they have global warming potentials (GWPs), 1430 and 3220 respectively, that are now considered to be too high by some regulatory bodies, especially for dispersive uses when they are released into the atmosphere.
- ODPs ozone depletion potentials
- GWPs global warming potentials
- R-134a One industrial area that has received particular attention recently has been the automotive air-conditioning sector where the use of R-134a has come under regulatory control as a result of the European F-Gas Regulations. Industry is developing a number of possible alternatives to R-134a in automotive air conditioning and other applications that have a low greenhouse warming potential (GWP) as well as a low ozone depletion potential (ODP). Many of these alternatives include hydrofluoropropenes, especially the tetrafluoropropenes, such as 2,3,3,3-tetrafluoropropene (R-1234yf) and 1,3,3,3-tetrafluoropropene (R-1234ze).
- GWP greenhouse warming potential
- ODP ozone depletion potential
- R-1234yf 2,3,3,3-tetrafluoropropene
- R-1234ze 1,3,3,3-tetrafluoropropene
- R-134a Although the proposed alternatives to R-134a have a low GWP, the toxicological status of many of the components, such as certain of the fluoropropenes, is unclear and they are unlikely to be acceptable for use in the MDI sector for many years, if at all.
- R-134a and R-227ea There are also other problems with R-134a and R-227ea.
- Drug suspensions give rise to a number of problems, such as nozzle blockage, agglomeration and sedimentation, the latter problem making it essential to shake the MDI thoroughly before use to ensure that the drug is evenly distributed in the propellant.
- the pharmaceutical active settles quickly following re-suspension in the propellant, as is often the case, then the propellant/drug composition must be delivered from the MDI shortly after shaking in order to ensure that the dose that is delivered contains an effective concentration of the pharmaceutical active.
- a polar excipient in the composition which either helps to dissolve the drug to form a solution or else enhances wetting of suspended drug particles to yield a better dispersed and more stable suspension.
- a preferred polar excipient is ethanol.
- ethanol ethanol
- the use of large amounts of ethanol can tend to result in a coarse spray having droplet sizes that are too large for acceptable penetration into the deep bronchiole passages of the lung.
- high levels of ethanol can have unacceptable irritancy to the mouth and throat, especially with younger users.
- Surfactants have also been included in some formulations that include drugs that are either insoluble or only sparingly soluble in the propellant, as these can also help to produce a more stable suspension.
- many of the toxicologically acceptable surfactants have sufficient solubility in either R-134a or R-227ea.
- ethanol has been added to the composition, where it functions not only as a wetter but also as a solvent for the surfactant. It would be beneficial to find a propellant/surfactant combination that allows for sufficient surfactant to be dissolved in the propellant without the inclusion of a polar excipient such as ethanol or with reduced levels of such an excipient.
- composition that is free of polar excipients, said composition comprising:
- a propellant component consisting essentially of 1,1-difluoroethane (R-152a),
- a surfactant component comprising at least one surfactant compound other than oleic acid
- a drug component consisting of salbutamol sulphate.
- composition consisting essentially of:
- a propellant component consisting essentially of 1,1-difluoroethane (R-152a),
- a surfactant component comprising at least one surfactant compound other than oleic acid
- a drug component consisting of salbutamol sulphate.
- compositions of the first and second aspects of the present invention are suitable for delivery from a pressured container, e.g. using a metered dose inhaler (MDI).
- MDI metered dose inhaler
- compositions of the invention are also free of perforated microstructures.
- compositions of the first and second aspects of the present invention typically comprise from 0.01 to 1.0 weight % of the drug component, from 96.5 to 99.94 weight % of the propellant component and from 0.05 to 2.5 weight % of the surfactant component.
- Preferred compositions comprise from 0.05 to 0.5 weight % of the drug component, from 97.5 to 99.85 weight % of the propellant component and from 0.1 to 2.0 weight % of the surfactant component.
- Particularly preferred pharmaceutical compositions comprise from 0.07 to 0.2 weight % of the drug component, from 98.8 to 99.73 weight % of the propellant component and from 0.2 to 1.0 weight % of the surfactant component. All percentages are based on the total weight of the pharmaceutical compositions.
- the propellant component in the pharmaceutical compositions of the first and second aspects of the present invention consists essentially of 1,1-difluoroethane (R-152a).
- the propellant component may include small amounts of propellant compounds in addition to the R-152a.
- the propellant component may additionally comprise one or more additional hydrofluorocarbon or hydrocarbon propellant compounds, e.g. selected from R-227ea, R-134a, difluoromethane (R-32), propane, butane, isobutane and dimethyl ether. If an additional propellant, compound is included, the R-152a will constitute at least 90 weight %, e.g. from 90 to 99 weight % of the propellant component.
- the R-152a will constitute at least 95 weight %, e.g. from 95 to 99 weight %, and more preferably at least 99 weight % of the propellant component.
- the propellant component is entirely R-152a, so that the pharmaceutical compositions of the invention comprise R-152a as the sole propellant.
- the surfactant component in the pharmaceutical compositions of the first and second aspects of the present invention comprises at least one surfactant compound other than oleic acid.
- the surfactant component can assist dispersion of the solid drug particles in the propellant.
- Suitable surfactants include esters of oleic acid, such as ethyl oleate, polyvinylpyrrolidone, esters of sorbitan, such as sorbitan monooleate and sorbitan trioleate, esters of myristic acid, such as isopropyl myristate, polyethylene glycols such as PEG 300, polyoxyethylene 20 sorbitan monooleate and monolaurate, propoxylated polyethyleneglycol and lecithin.
- the preferred surfactant is polyvinylpyrrolidone.
- the surfactant component consists essentially of at least one surfactant compound other than oleic acid and more preferably consists entirely of at least one surfactant compound other than oleic acid.
- the pharmaceutical compositions of the first and second aspects of the present invention are free of oleic acid.
- the drug component in the pharmaceutical compositions of the present invention consists entirely of salbutamol sulphate, so that the only drug in the pharmaceutical compositions is salbutamol sulphate.
- the salbutamol sulphate does not dissolve or dissolve significantly in the propellant component but forms a dispersion or suspension in the propellant/surfactant mixture.
- the suspended drug particles preferably have a diameter of less than 100 microns.
- the pharmaceutical compositions of the invention are also free of perforated microstructures.
- the pharmaceutical composition of the first aspect of the present invention is free of polar excipients.
- Polar excipients such as ethanol
- MDIs metered dose inhalers
- They are also referred to as solvents, co-solvents, carrier solvents and adjuvants. Their inclusion can serve to solubilise the surfactant or the drug in the propellant and/or inhibit deposition of drug particles on the surfaces of the metered dose inhaler that are contacted by the pharmaceutical composition as it passes from the container in which it is stored to the nozzle outlet.
- They are also used as bulking agents in two-stage filling processes where the drug is mixed with a suitable polar excipient.
- the most commonly used polar excipient is ethanol.
- R-152a as the propellant reduces the need for polar excipients and allows compositions that contain very small amounts of polar excipients or that are free of polar excipients altogether to be prepared that still deliver good performance when delivered from a medication delivery device, such as a metered dose inhaler (MDI).
- MDI metered dose inhaler
- the pharmaceutical composition of the first aspect of the present invention preferably consists essentially of and more preferably consists entirely of the three listed components.
- consists essentially of we mean that at least 95 weight %, more preferably at least 98 weight % and especially at least 99 weight % of the pharmaceutical composition consists of the three listed components.
- the pharmaceutical composition of the second aspect of the present invention consists essentially of and preferably consists entirely of the three listed components.
- consists essentially of we mean that at least 95 weight %, more preferably at least 98 weight % and especially at least 99 weight % of the pharmaceutical composition consists of the three listed components.
- the pharmaceutical composition of the second aspect of the present invention optionally contains at least one polar excipient.
- any polar material that is pharmaceutically acceptable may be employed as a polar excipient.
- suitable polar excipients include alcohols, such as ethyl alcohol (ethanol) and glycerol, and glycols, such as propylene glycol, polyethylene glycols and polypropylene glycols.
- the most preferred polar excipient is ethanol, which may be used together with other polar excipients but is preferably used alone.
- the pharmaceutical composition of the second aspect of the present invention is free of any polar excipients such as ethanol.
- the mandatory and preferred amounts of R-152a in the propellant component are as discussed above.
- the propellant component will consist entirely of R-152a and the surfactant component will consist entirely of one or more surfactant compounds other than oleic acid even when a polar excipient is present.
- compositions of the first and second aspects of the present invention find particular utility in the delivery of salbutamol sulphate from a pressurised aerosol container using a metered dose inhaler (MDI).
- MDI metered dose inhaler
- the propellant component functions to deliver the drug as a fine aerosol spray.
- the present invention provides a pharmaceutical composition for delivery from a pressurized container that is free of polar excipients comprising:
- a propellant component consisting of 1/1-difluoroethane (R-152a);
- a surfactant component consisting of at least one surfactant compound other than oleic acid
- a drug component consisting of salbutamol sulphate.
- the pharmaceutical composition preferably consists essentially of and more preferably consists entirely of the three listed components.
- the surfactant component is preferably polyvinylpyrrolidone.
- compositions of the invention may also comprise one or more other additives of the type that are conventionally used in drug formulations for pressurised MDIs, such as valve lubricants. Where other additives are included in the pharmaceutical compositions, they are normally used in amounts that are conventional in the art.
- the pharmaceutical compositions of the invention are normally stored in pressurised containers or canisters which are to be used in association with a medication delivery device. When so stored, the pharmaceutical compositions are normally in the liquid state.
- the pressurised container is designed for use in a metered dose inhaler (MDI).
- a third aspect of the present invention provides pressurised containers holding respectively the pharmaceutical compositions of the first and second aspects of the present invention.
- the present invention provides medication delivery devices, especially metered dose inhalers, having pressurised containers respectively holding the pharmaceutical compositions of the first and second aspects of the present invention.
- the present invention provides a pressurised container holding a pharmaceutical composition that is free of polar excipients comprising:
- a propellant component consisting of 1,1-difluoroethane (R-152a);
- a surfactant component consisting of at least one surfactant compound other than oleic acid
- a drug component consisting of salbutamol sulphate.
- the present invention provides a medication delivery device, especially a metered dose inhaler, having a pressurised container holding a pharmaceutical composition that is free of polar excipients comprising:
- a propellant component consisting of 1,1-difluoroethane (R-152a);
- a surfactant component consisting of at least one surfactant compound other than oleic acid
- a drug component consisting of salbutamol sulphate.
- the pharmaceutical composition preferably consists essentially of and more preferably consists entirely of the three listed components.
- the surfactant component is preferably polyvinylpyrrolidone.
- compositions of the present invention are for use in medicine for treating a patient suffering or likely to suffer from a respiratory disorder and especially asthma.
- the present invention also provides a method for treating a patient suffering or likely to suffer from a respiratory disorder, especially asthma, which comprises administering to the patient a therapeutically or prophylactically effective amount of a pharmaceutical composition as discussed above.
- the pharmaceutical composition is preferably delivered to the patient using a MDI.
- the pharmaceutical compositions of the invention can be prepared by a simple blending operation in which the R-152a-containing propellant component, the surfactant component, and the salbutamol sulphate are mixed together in the required proportions in a suitable mixing vessel. Mixing can be promoted by stirring as is common in the art. The three components can be charged to the mixing vessel and then mixed together in one go. Alternatively, a concentrate of the salbutamol sulphate and the surfactant component in a proportion of the propellant component can be prepared first in the vessel and the remainder of the propellant component then mixed in with the concentrate. Conveniently, the R-152a-containing propellant component is liquefied to aid mixing. If the pharmaceutical composition is made in a separate mixing vessel, it can then be transferred to pressurised containers for storage, such as pressurised containers that are used as part of medication delivery devices and especially MDIs.
- compositions of the invention can also be prepared within the confines of a pressurised container, such as an aerosol canister or vial, from which the compositions are ultimately released as an aerosol spray using a medication delivery device, such as a MDI.
- a pressurised container such as an aerosol canister or vial
- a medication delivery device such as a MDI.
- a weighed amount of the salbutamol sulphate is introduced into the open container.
- a valve is then crimped onto the container and the 152a-containing propellant component, in liquid form, introduced through the valve into the container under pressure, optionally after first evacuating the container through the valve.
- the surfactant component can be mixed with the salbutamol sulphate or, alternatively, introduced into the container after the valve has been fitted, either alone or as a premix with the propellant component.
- the whole mixture can then be treated to disperse the drug in the propellant or propellant/surfactant mixture, e.g. by vigorous shaking or using
- a first amount of the 152a-containing propellant component is mixed with the salbutamol sulphate and a second amount of the 152a-containing propellant component is mixed with the surfactant component, the first and second amounts together providing the required amount of propellant.
- the salbutamol sulphate/propellant component premix and the surfactant component/propellant component premix are then blended together to form the final pharmaceutical composition.
- salbutamol sulphate and surfactant component are used as discrete components and are not completed to one another prior to mixing with the propellant component, e.g. by a method including dissolving the salbutamol sulphate and the surfactant component in a solvent for both compounds to form a solution and then removing the solvent to leave the complex.
- the canister may be filled with enough of the pharmaceutical composition to provide for a plurality of dosages.
- the pressurized aerosol canisters that are used in MDIs typically contain 50 to 150 individual dosages.
- the problem can arise that the suspended drug particles deposit on the interior surfaces of the canister and the valve of the drug delivery device.
- This problem can necessitate providing the canister interior with a special lining or coating, such as a fluoropolymer coating, and maxing the valves from specialist polymer materials.
- the pharmaceutical compositions of the invention are capable of forming a stable dispersion of the drug, thereby avoiding the problem of drug deposition, and yet deliver the drug as a sufficiently fine aerosol mist that is able to deliver the drug deep into the lung.
- the solubility of various surfactants in R-134a and R-152a was investigated.
- the solubility was investigated by adding an excess of the surfactant (around 2 grams) to 200 g of the liquid propellant in a pressurised vessel.
- the vessel was equilibrated at 20° C. for a period of a few hours before decanting a weighed sample of the saturated supernatant liquid propellant through a filter into a clean vessel.
- the propellant was slowly removed by evaporation and the residue taken up in a small quantity of dichloromethane.
- the dichloromethane containing the dissolved residue was transferred to a weighed platinum crucible and heated (up to around 100° C.) to remove the solvent.
- the weighed, solvent-free residue represented the quantity of dissolved surfactant in the propellant.
- Table 1 The results are shown in Table 1 below.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
- This application is a continuation of U.S. application Ser. No. 14/784,798, filed on 15 Oct. 2015, which is the US National Phase under 35 U.S.C. § 371 of International Application No. PCT/GB2014/051221, filed Apr. 17, 2014, designating the U.S. and published in English on Oct. 23, 2014, as WO 2014/170689, which claims priority to UK Appl. No. 1306984.4, filed on Apr. 17, 2013, each of which is incorporated by reference in its entirety.
- The present invention relates to a pharmaceutical composition comprising salbutamol sulphate, a propellant and a surfactant. The composition is suitable for delivering the salbutamol sulphate from a pressurised aerosol container using a metered dose inhaler (MDI).
- MDIs are the most significant type of inhalation drug delivery system and are well known to those skilled in the art. They are designed to deliver, on demand, a discrete and accurate amount of a drug to the respiratory tract of a patient using a liquefied propellant in which the drug is dissolved, suspended or dispersed. The design and operation of MDIs is described in many standard textbooks and in the patent literature. They all comprise a pressurised container that holds the drug formulation, a nozzle and a valve assembly that is capable of dispensing a controlled quantity of the drug through the nozzle when it is activated. All of these components are typically located in a housing that is equipped with a mouth piece. The drug formulation will comprise a propellant, in which the drug is dissolved, suspended or dispersed, and may contain other materials such as polar excipients, surfactants and preservatives.
- In order for a propellant to function satisfactorily in MDIs, it needs to have a number of properties. These include an appropriate boiling point and vapour pressure so that it can be liquefied in a closed container at room temperature but develop a high enough pressure when the MDI is activated to deliver the drug as an atomised formulation even at low ambient temperatures. Further, the propellant should be of low acute and chronic toxicity and have a high cardiac sensitisation threshold. It should have a high degree of chemical stability in contact with the drug, the container and the metallic and non-metallic components of the MDI device, and have a low propensity to extract low molecular weight substances from any elastomeric materials in the MDI device. The propellant should also be capable of maintaining the drug in a homogeneous solution, in a stable suspension or in a stable dispersion for a sufficient time to permit reproducible delivery of the drug in use. When the drug is in suspension in the propellant, the density of the liquid propellant is desirably similar to that of the solid drug in order to avoid rapid sinking or floating of the drug particles in the liquid. Finally, the propellant should not present a significant flammability risk to the patient in use. In particular, it should form a non-flammable or low flammability mixture when mixed with air in the respiratory tract.
- Dichlorodifluoromethane (R-12) possesses a suitable combination of properties and was for many years the most widely used MDI propellant, often blended with trichlorofluoromethane (R-11). Due to international concern that fully and partially halogenated chlorofluorocarbons (CFCs), such as dichlorodifluoromethane and trichlorofluoromethane, were damaging the earth's protective ozone layer, many countries entered into an agreement, the Montreal Protocol, stipulating that their manufacture and use should be severely restricted and eventually phased out completely. Dichlorodifluoromethane and trichlorofluoromethane were phased out for refrigeration use in the 1990's, but are still used in small quantities in the MDI sector as a result of an essential use exemption in the Montreal Protocol.
- 1,1,1,2-tetrafluoroethane (R-134a) was introduced as a replacement refrigerant and MDI propellant for R-12. 1,1,1,2,3,3,3-heptafluoropropane (R-227ea) was also introduced as a replacement for dichlorotetrafluoroethane (R-114) in the MDI sector and is sometimes blended with R-134a for this application.
- Although R-134a and R-227ea have low ozone depletion potentials (ODPs), they have global warming potentials (GWPs), 1430 and 3220 respectively, that are now considered to be too high by some regulatory bodies, especially for dispersive uses when they are released into the atmosphere.
- One industrial area that has received particular attention recently has been the automotive air-conditioning sector where the use of R-134a has come under regulatory control as a result of the European F-Gas Regulations. Industry is developing a number of possible alternatives to R-134a in automotive air conditioning and other applications that have a low greenhouse warming potential (GWP) as well as a low ozone depletion potential (ODP). Many of these alternatives include hydrofluoropropenes, especially the tetrafluoropropenes, such as 2,3,3,3-tetrafluoropropene (R-1234yf) and 1,3,3,3-tetrafluoropropene (R-1234ze).
- Although the proposed alternatives to R-134a have a low GWP, the toxicological status of many of the components, such as certain of the fluoropropenes, is unclear and they are unlikely to be acceptable for use in the MDI sector for many years, if at all.
- There are also other problems with R-134a and R-227ea. Most pharmaceutical actives for treating respiratory disorders, such as asthma, tend not to dissolve well in either R-134a or R-227ea and have to be handled as suspensions in the propellant. Drug suspensions give rise to a number of problems, such as nozzle blockage, agglomeration and sedimentation, the latter problem making it essential to shake the MDI thoroughly before use to ensure that the drug is evenly distributed in the propellant. Furthermore, if the pharmaceutical active settles quickly following re-suspension in the propellant, as is often the case, then the propellant/drug composition must be delivered from the MDI shortly after shaking in order to ensure that the dose that is delivered contains an effective concentration of the pharmaceutical active.
- The problem of poorly dissolving drugs has been addressed by including a polar excipient: in the composition which either helps to dissolve the drug to form a solution or else enhances wetting of suspended drug particles to yield a better dispersed and more stable suspension. A preferred polar excipient is ethanol. However, the use of large amounts of ethanol can tend to result in a coarse spray having droplet sizes that are too large for acceptable penetration into the deep bronchiole passages of the lung. Further, high levels of ethanol can have unacceptable irritancy to the mouth and throat, especially with younger users. Clearly it would be advantageous to reduce the amount of ethanol that is required to produce an acceptable formulation. It would be better still if the use of ethanol could be avoided altogether.
- Surfactants have also been included in some formulations that include drugs that are either insoluble or only sparingly soluble in the propellant, as these can also help to produce a more stable suspension. Unfortunately, many of the toxicologically acceptable surfactants have sufficient solubility in either R-134a or R-227ea. As a result, ethanol has been added to the composition, where it functions not only as a wetter but also as a solvent for the surfactant. It would be beneficial to find a propellant/surfactant combination that allows for sufficient surfactant to be dissolved in the propellant without the inclusion of a polar excipient such as ethanol or with reduced levels of such an excipient.
- There is a need for a MDI aerosol formulation that has a reduced GWP in comparison with R-134a and R-227ea, that has acceptable flammability and toxicity performance, which forms stable suspensions and that has reduced irritancy.
- According to a first aspect of the present invention there is provided a pharmaceutical composition that is free of polar excipients, said composition comprising:
- a propellant component consisting essentially of 1,1-difluoroethane (R-152a),
- a surfactant component comprising at least one surfactant compound other than oleic acid; and
- a drug component consisting of salbutamol sulphate.
- According to a second aspect of the present invention there is provided a pharmaceutical composition consisting essentially of:
- a propellant component consisting essentially of 1,1-difluoroethane (R-152a),
- a surfactant component comprising at least one surfactant compound other than oleic acid; and
- a drug component consisting of salbutamol sulphate.
- The pharmaceutical compositions of the first and second aspects of the present invention are suitable for delivery from a pressured container, e.g. using a metered dose inhaler (MDI).
- The pharmaceutical compositions of the invention are also free of perforated microstructures.
- Although the disclosure hereof is detailed and exact to enable those skilled in the art to practice the invention, the physical embodiments herein disclosed merely exemplify the invention which may be embodied in other specific structures. While the preferred embodiment has been described, the details may be changed without departing from the invention, which is defined by the claims.
- The pharmaceutical compositions of the first and second aspects of the present invention typically comprise from 0.01 to 1.0 weight % of the drug component, from 96.5 to 99.94 weight % of the propellant component and from 0.05 to 2.5 weight % of the surfactant component. Preferred compositions comprise from 0.05 to 0.5 weight % of the drug component, from 97.5 to 99.85 weight % of the propellant component and from 0.1 to 2.0 weight % of the surfactant component. Particularly preferred pharmaceutical compositions comprise from 0.07 to 0.2 weight % of the drug component, from 98.8 to 99.73 weight % of the propellant component and from 0.2 to 1.0 weight % of the surfactant component. All percentages are based on the total weight of the pharmaceutical compositions.
- The propellant component in the pharmaceutical compositions of the first and second aspects of the present invention consists essentially of 1,1-difluoroethane (R-152a). Thus, we do not exclude the possibility that the propellant component may include small amounts of propellant compounds in addition to the R-152a. For example, the propellant component may additionally comprise one or more additional hydrofluorocarbon or hydrocarbon propellant compounds, e.g. selected from R-227ea, R-134a, difluoromethane (R-32), propane, butane, isobutane and dimethyl ether. If an additional propellant, compound is included, the R-152a will constitute at least 90 weight %, e.g. from 90 to 99 weight % of the propellant component. Preferably, the R-152a will constitute at least 95 weight %, e.g. from 95 to 99 weight %, and more preferably at least 99 weight % of the propellant component. In an especially preferred embodiment, the propellant component is entirely R-152a, so that the pharmaceutical compositions of the invention comprise R-152a as the sole propellant.
- The surfactant component in the pharmaceutical compositions of the first and second aspects of the present invention comprises at least one surfactant compound other than oleic acid. The surfactant component can assist dispersion of the solid drug particles in the propellant. Suitable surfactants include esters of oleic acid, such as ethyl oleate, polyvinylpyrrolidone, esters of sorbitan, such as sorbitan monooleate and sorbitan trioleate, esters of myristic acid, such as isopropyl myristate, polyethylene glycols such as PEG 300, polyoxyethylene 20 sorbitan monooleate and monolaurate, propoxylated polyethyleneglycol and lecithin. The preferred surfactant is polyvinylpyrrolidone.
- Preferably, the surfactant component consists essentially of at least one surfactant compound other than oleic acid and more preferably consists entirely of at least one surfactant compound other than oleic acid. Thus, in a preferred embodiment, the pharmaceutical compositions of the first and second aspects of the present invention are free of oleic acid.
- By the terms “consists of” and “consisting of” as used herein, we are intending to exclude the presence of additional components. Thus, the drug component in the pharmaceutical compositions of the present invention consists entirely of salbutamol sulphate, so that the only drug in the pharmaceutical compositions is salbutamol sulphate. The salbutamol sulphate does not dissolve or dissolve significantly in the propellant component but forms a dispersion or suspension in the propellant/surfactant mixture. The suspended drug particles preferably have a diameter of less than 100 microns. The pharmaceutical compositions of the invention are also free of perforated microstructures.
- The pharmaceutical composition of the first aspect of the present invention is free of polar excipients. Polar excipients, such as ethanol, are used routinely in pharmaceutical compositions for treating respiratory disorders that are delivered using metered dose inhalers (MDIs). They are also referred to as solvents, co-solvents, carrier solvents and adjuvants. Their inclusion can serve to solubilise the surfactant or the drug in the propellant and/or inhibit deposition of drug particles on the surfaces of the metered dose inhaler that are contacted by the pharmaceutical composition as it passes from the container in which it is stored to the nozzle outlet. They are also used as bulking agents in two-stage filling processes where the drug is mixed with a suitable polar excipient. The most commonly used polar excipient is ethanol.
- The present inventors have discovered that for salbutamol sulphate, the use of R-152a as the propellant reduces the need for polar excipients and allows compositions that contain very small amounts of polar excipients or that are free of polar excipients altogether to be prepared that still deliver good performance when delivered from a medication delivery device, such as a metered dose inhaler (MDI).
- The pharmaceutical composition of the first aspect of the present invention preferably consists essentially of and more preferably consists entirely of the three listed components. By the term “consists essentially of”, we mean that at least 95 weight %, more preferably at least 98 weight % and especially at least 99 weight % of the pharmaceutical composition consists of the three listed components.
- The pharmaceutical composition of the second aspect of the present invention consists essentially of and preferably consists entirely of the three listed components. By the term “consists essentially of”, we mean that at least 95 weight %, more preferably at least 98 weight % and especially at least 99 weight % of the pharmaceutical composition consists of the three listed components.
- Although not preferred, the pharmaceutical composition of the second aspect of the present invention optionally contains at least one polar excipient. In principal, any polar material that is pharmaceutically acceptable may be employed as a polar excipient. Examples of suitable polar excipients include alcohols, such as ethyl alcohol (ethanol) and glycerol, and glycols, such as propylene glycol, polyethylene glycols and polypropylene glycols. The most preferred polar excipient is ethanol, which may be used together with other polar excipients but is preferably used alone. Preferably, the pharmaceutical composition of the second aspect of the present invention is free of any polar excipients such as ethanol.
- Where a polar excipient is employed, the mandatory and preferred amounts of R-152a in the propellant component are as discussed above. Preferably, the propellant component will consist entirely of R-152a and the surfactant component will consist entirely of one or more surfactant compounds other than oleic acid even when a polar excipient is present.
- The pharmaceutical compositions of the first and second aspects of the present invention find particular utility in the delivery of salbutamol sulphate from a pressurised aerosol container using a metered dose inhaler (MDI). In this application, the propellant component functions to deliver the drug as a fine aerosol spray.
- In an especially preferred embodiment, the present invention provides a pharmaceutical composition for delivery from a pressurized container that is free of polar excipients comprising:
- a propellant component consisting of 1/1-difluoroethane (R-152a);
- a surfactant component consisting of at least one surfactant compound other than oleic acid; and
- a drug component consisting of salbutamol sulphate.
- In this especially preferred embodiment, the pharmaceutical composition preferably consists essentially of and more preferably consists entirely of the three listed components. The surfactant component is preferably polyvinylpyrrolidone.
- The pharmaceutical compositions of the invention may also comprise one or more other additives of the type that are conventionally used in drug formulations for pressurised MDIs, such as valve lubricants. Where other additives are included in the pharmaceutical compositions, they are normally used in amounts that are conventional in the art.
- The pharmaceutical compositions of the invention are normally stored in pressurised containers or canisters which are to be used in association with a medication delivery device. When so stored, the pharmaceutical compositions are normally in the liquid state. In a preferred embodiment, the pressurised container is designed for use in a metered dose inhaler (MDI).
- Accordingly, a third aspect of the present invention provides pressurised containers holding respectively the pharmaceutical compositions of the first and second aspects of the present invention. In a fourth aspect, the present invention provides medication delivery devices, especially metered dose inhalers, having pressurised containers respectively holding the pharmaceutical compositions of the first and second aspects of the present invention.
- In an especially preferred embodiment, the present invention provides a pressurised container holding a pharmaceutical composition that is free of polar excipients comprising:
- a propellant component consisting of 1,1-difluoroethane (R-152a);
- a surfactant component consisting of at least one surfactant compound other than oleic acid; and
- a drug component consisting of salbutamol sulphate.
- In another especially preferred embodiment, the present invention provides a medication delivery device, especially a metered dose inhaler, having a pressurised container holding a pharmaceutical composition that is free of polar excipients comprising:
- a propellant component consisting of 1,1-difluoroethane (R-152a);
- a surfactant component consisting of at least one surfactant compound other than oleic acid; and
- a drug component consisting of salbutamol sulphate.
- In these especially preferred embodiments, the pharmaceutical composition preferably consists essentially of and more preferably consists entirely of the three listed components. The surfactant component is preferably polyvinylpyrrolidone.
- The typical and preferred proportions of the drug component, propellant component and surfactant component in the pharmaceutical composition of these especially preferred embodiments are as discussed above.
- The pharmaceutical compositions of the present invention are for use in medicine for treating a patient suffering or likely to suffer from a respiratory disorder and especially asthma.
- Accordingly, the present invention also provides a method for treating a patient suffering or likely to suffer from a respiratory disorder, especially asthma, which comprises administering to the patient a therapeutically or prophylactically effective amount of a pharmaceutical composition as discussed above. The pharmaceutical composition is preferably delivered to the patient using a MDI.
- The pharmaceutical compositions of the invention can be prepared by a simple blending operation in which the R-152a-containing propellant component, the surfactant component, and the salbutamol sulphate are mixed together in the required proportions in a suitable mixing vessel. Mixing can be promoted by stirring as is common in the art. The three components can be charged to the mixing vessel and then mixed together in one go. Alternatively, a concentrate of the salbutamol sulphate and the surfactant component in a proportion of the propellant component can be prepared first in the vessel and the remainder of the propellant component then mixed in with the concentrate. Conveniently, the R-152a-containing propellant component is liquefied to aid mixing. If the pharmaceutical composition is made in a separate mixing vessel, it can then be transferred to pressurised containers for storage, such as pressurised containers that are used as part of medication delivery devices and especially MDIs.
- The pharmaceutical compositions of the invention can also be prepared within the confines of a pressurised container, such as an aerosol canister or vial, from which the compositions are ultimately released as an aerosol spray using a medication delivery device, such as a MDI. In this method, a weighed amount of the salbutamol sulphate is introduced into the open container. A valve is then crimped onto the container and the 152a-containing propellant component, in liquid form, introduced through the valve into the container under pressure, optionally after first evacuating the container through the valve. The surfactant component can be mixed with the salbutamol sulphate or, alternatively, introduced into the container after the valve has been fitted, either alone or as a premix with the propellant component. The whole mixture can then be treated to disperse the drug in the propellant or propellant/surfactant mixture, e.g. by vigorous shaking or using an ultrasonic bath. Suitable canisters may be made of plastics, metal or glass.
- In yet another preparative method, a first amount of the 152a-containing propellant component is mixed with the salbutamol sulphate and a second amount of the 152a-containing propellant component is mixed with the surfactant component, the first and second amounts together providing the required amount of propellant. The salbutamol sulphate/propellant component premix and the surfactant component/propellant component premix are then blended together to form the final pharmaceutical composition.
- It will be appreciated that variations of the above described methods may be employed to prepare the pharmaceutical compositions of the invention. However, it is important that the salbutamol sulphate and surfactant component are used as discrete components and are not completed to one another prior to mixing with the propellant component, e.g. by a method including dissolving the salbutamol sulphate and the surfactant component in a solvent for both compounds to form a solution and then removing the solvent to leave the complex.
- The canister may be filled with enough of the pharmaceutical composition to provide for a plurality of dosages. The pressurized aerosol canisters that are used in MDIs, typically contain 50 to 150 individual dosages.
- For pharmaceutical compositions that comprise a drug in suspension in a propellant, the problem can arise that the suspended drug particles deposit on the interior surfaces of the canister and the valve of the drug delivery device. This problem can necessitate providing the canister interior with a special lining or coating, such as a fluoropolymer coating, and maxing the valves from specialist polymer materials. However, the pharmaceutical compositions of the invention are capable of forming a stable dispersion of the drug, thereby avoiding the problem of drug deposition, and yet deliver the drug as a sufficiently fine aerosol mist that is able to deliver the drug deep into the lung.
- The present invention is now illustrated but not limited by the following examples.
- The solubility of various surfactants in R-134a and R-152a was investigated. The solubility was investigated by adding an excess of the surfactant (around 2 grams) to 200 g of the liquid propellant in a pressurised vessel. The vessel was equilibrated at 20° C. for a period of a few hours before decanting a weighed sample of the saturated supernatant liquid propellant through a filter into a clean vessel. The propellant was slowly removed by evaporation and the residue taken up in a small quantity of dichloromethane. The dichloromethane containing the dissolved residue was transferred to a weighed platinum crucible and heated (up to around 100° C.) to remove the solvent. The weighed, solvent-free residue represented the quantity of dissolved surfactant in the propellant. The results are shown in Table 1 below.
-
TABLE 1 NVR Surfactant Refrigerant Observation result None 152a None N/D Tween 152a Sank to the bottom 0.6% some dispersed in 152a Tween 134a Floated on top coated the 0.25% sides of the vessel some dispersed into the K134a Span 80 152a Sunk to the bottom 0.22% Dispersed into the 152a Span 80 134a Floated on top and 0.07% some left in bottom Polyvinyl- 152a Sunk to the bottom stayed 0.01% pyrrolidone in original form Polyvinyl- 134a Floated on top formed 0.005% pyrrolidone a hard brittle layer Peg 400 152a NO layers observed possible 1.18% dispersed into 152a Peg 400 134a NO layers observed possible 1.08% dispersed into 152a - It is evident from the table above that PVP, Tween and Span all show significant increases in solubility in R-152a in comparison with R134a. Whilst PEG400 also shows some solubility increase, it is not as pronounced.
- The foregoing is considered as illustrative only of the principles of the invention. Furthermore, since numerous modifications and changes will readily occur to those skilled in the art, it is not desired to limit the invention to the exact construction and operation shown and described. While the preferred embodiment has been described, the details may be changed without departing from the invention, which is defined by the claims.
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/782,143 US20200179310A1 (en) | 2013-04-17 | 2020-02-05 | Compositions comprising salbutamol sulphate |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1306984.4 | 2013-04-17 | ||
GBGB1306984.4A GB201306984D0 (en) | 2013-04-17 | 2013-04-17 | Composition |
PCT/GB2014/051221 WO2014170689A1 (en) | 2013-04-17 | 2014-04-17 | Composition comprising salbutamol sulphate |
US201514784798A | 2015-10-15 | 2015-10-15 | |
US16/782,143 US20200179310A1 (en) | 2013-04-17 | 2020-02-05 | Compositions comprising salbutamol sulphate |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2014/051221 Continuation WO2014170689A1 (en) | 2013-04-17 | 2014-04-17 | Composition comprising salbutamol sulphate |
US14/784,798 Continuation US10959965B2 (en) | 2013-04-17 | 2014-04-17 | Composition comprising salbutamol sulphate |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200179310A1 true US20200179310A1 (en) | 2020-06-11 |
Family
ID=48537398
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/784,798 Active US10959965B2 (en) | 2013-04-17 | 2014-04-17 | Composition comprising salbutamol sulphate |
US16/782,143 Pending US20200179310A1 (en) | 2013-04-17 | 2020-02-05 | Compositions comprising salbutamol sulphate |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/784,798 Active US10959965B2 (en) | 2013-04-17 | 2014-04-17 | Composition comprising salbutamol sulphate |
Country Status (12)
Country | Link |
---|---|
US (2) | US10959965B2 (en) |
EP (1) | EP2986283B1 (en) |
JP (1) | JP6085716B2 (en) |
CN (1) | CN105120850B (en) |
AU (1) | AU2014255466B2 (en) |
BR (1) | BR112015026053B1 (en) |
CA (1) | CA2909431C (en) |
ES (1) | ES2632814T3 (en) |
GB (1) | GB201306984D0 (en) |
MX (1) | MX370890B (en) |
WO (1) | WO2014170689A1 (en) |
ZA (1) | ZA201507717B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3701940A1 (en) | 2015-12-04 | 2020-09-02 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition |
WO2018051131A1 (en) | 2016-09-19 | 2018-03-22 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
CA3037080C (en) | 2016-09-19 | 2021-05-18 | Mexichem Fluor S.A. De C.V. | Stable pharmaceutical compositions comprising indacaterol and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis) |
ES2957459T3 (en) | 2016-09-19 | 2024-01-19 | Mexichem Fluor Sa De Cv | Pharmaceutical composition comprising glycopyrrolate |
GB2554089A (en) * | 2016-09-19 | 2018-03-28 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
GB2573297A (en) * | 2018-04-30 | 2019-11-06 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
FR3130554A1 (en) | 2021-12-20 | 2023-06-23 | Aptar France Sas | Pharmaceutical composition comprising salbutamol |
FR3137830A1 (en) | 2022-07-13 | 2024-01-19 | Aptar France Sas | Pharmaceutical composition comprising salbutamol |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130104881A1 (en) * | 2011-10-31 | 2013-05-02 | Laboratorio Pablo Cassara S.R.L. | Stabilized Metered Dose Inhaler |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
US5252720A (en) | 1989-03-06 | 1993-10-12 | Board Of Regents, The University Of Texas System | Metal complexes of water soluble texaphyrins |
GB9001019D0 (en) * | 1990-01-17 | 1990-03-14 | Euro Celtique Sa | Pharmaceutical aerosol |
IE67185B1 (en) * | 1990-02-02 | 1996-03-06 | Fisons Plc | Propellant compositions |
DE4003272A1 (en) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | NEW GAS MIXTURES AND THEIR USE IN MEDICINE PREPARATIONS |
DK0617610T3 (en) | 1991-12-18 | 1997-10-06 | Minnesota Mining & Mfg | Suspension aerosol. |
US7105152B1 (en) | 1991-12-18 | 2006-09-12 | 3M Innovative Properties Company | Suspension aerosol formulations |
ATE236617T1 (en) * | 1994-12-22 | 2003-04-15 | Astrazeneca Ab | AEROSOL MEDICINAL FORMULATIONS |
ES2276736T3 (en) * | 1995-04-14 | 2007-07-01 | Smithkline Beecham Corporation | DOSE METER INHALER FOR FLUCTICASONE PROPIONATE. |
EP1019020A1 (en) * | 1997-09-29 | 2000-07-19 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
US20060165606A1 (en) * | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US6103266A (en) | 1998-04-22 | 2000-08-15 | Tapolsky; Gilles H. | Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
US6451285B2 (en) | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
PT1102579E (en) | 1998-08-04 | 2003-07-31 | Jago Res Ag | MEDICINAL AEROSOL FORMULATIONS |
GB2392915B (en) | 1999-09-11 | 2004-04-28 | Glaxo Group Ltd | Pharmaceutical formulation of fluticasone propionate |
US6432415B1 (en) | 1999-12-17 | 2002-08-13 | Axrix Laboratories, Inc. | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
CN1144582C (en) | 2000-11-28 | 2004-04-07 | 中国药科大学 | Medical aerosol without freon for treating diseases in respiratory system |
CN1216600C (en) * | 2002-04-24 | 2005-08-31 | 信谊药厂 | Levo-salbutamol hydrochloride aerosol and its prepn. |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
GB0323685D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
WO2006004646A1 (en) | 2004-06-28 | 2006-01-12 | Nektar Therapeutics | Aerosol formulation comprising nicotine salt |
WO2007020204A2 (en) | 2005-08-12 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate |
DE102006053374A1 (en) * | 2006-02-09 | 2007-08-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical formulation for aerosols with two or more active substances and at least one surface-active substance |
DE102006017320A1 (en) * | 2006-04-11 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant |
MX2011004730A (en) * | 2008-11-04 | 2011-05-30 | Cipla Ltd | Pharmaceutical aerosol composition. |
GB0915106D0 (en) | 2009-08-28 | 2009-10-07 | Glaxo Group Ltd | Process |
GB201108039D0 (en) | 2011-05-13 | 2011-06-29 | Mexichem Amanco Holding Sa | Compositions |
GB201117619D0 (en) | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
GB201117621D0 (en) | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
-
2013
- 2013-04-17 GB GBGB1306984.4A patent/GB201306984D0/en not_active Ceased
-
2014
- 2014-04-17 CN CN201480021833.4A patent/CN105120850B/en active Active
- 2014-04-17 US US14/784,798 patent/US10959965B2/en active Active
- 2014-04-17 EP EP14726400.6A patent/EP2986283B1/en active Active
- 2014-04-17 CA CA2909431A patent/CA2909431C/en active Active
- 2014-04-17 ES ES14726400.6T patent/ES2632814T3/en active Active
- 2014-04-17 JP JP2016508244A patent/JP6085716B2/en active Active
- 2014-04-17 BR BR112015026053-5A patent/BR112015026053B1/en active IP Right Grant
- 2014-04-17 WO PCT/GB2014/051221 patent/WO2014170689A1/en active Application Filing
- 2014-04-17 AU AU2014255466A patent/AU2014255466B2/en active Active
- 2014-04-17 MX MX2015014513A patent/MX370890B/en active IP Right Grant
-
2015
- 2015-10-15 ZA ZA2015/07717A patent/ZA201507717B/en unknown
-
2020
- 2020-02-05 US US16/782,143 patent/US20200179310A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130104881A1 (en) * | 2011-10-31 | 2013-05-02 | Laboratorio Pablo Cassara S.R.L. | Stabilized Metered Dose Inhaler |
Non-Patent Citations (1)
Title |
---|
Solid: Oxford reference: https://www.oxfordreference.com/display/10.1093/oi/authority.20110803100517133. (Year: 2024) * |
Also Published As
Publication number | Publication date |
---|---|
CN105120850B (en) | 2018-07-27 |
BR112015026053A8 (en) | 2020-01-14 |
BR112015026053B1 (en) | 2023-01-10 |
WO2014170689A1 (en) | 2014-10-23 |
CA2909431C (en) | 2017-10-10 |
CA2909431A1 (en) | 2014-10-23 |
EP2986283A1 (en) | 2016-02-24 |
AU2014255466A1 (en) | 2015-11-05 |
EP2986283B1 (en) | 2017-05-17 |
CN105120850A (en) | 2015-12-02 |
JP6085716B2 (en) | 2017-02-22 |
GB201306984D0 (en) | 2013-05-29 |
US10959965B2 (en) | 2021-03-30 |
MX370890B (en) | 2020-01-09 |
MX2015014513A (en) | 2016-02-09 |
AU2014255466B2 (en) | 2016-07-07 |
US20160058714A1 (en) | 2016-03-03 |
BR112015026053A2 (en) | 2017-07-25 |
JP2016518364A (en) | 2016-06-23 |
ZA201507717B (en) | 2023-12-20 |
ES2632814T3 (en) | 2017-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10039828B2 (en) | Compositions comprising salbutamol sulphate | |
US20200179310A1 (en) | Compositions comprising salbutamol sulphate | |
US10258568B2 (en) | Pharmaceutical compositions | |
US11559506B2 (en) | Pharmaceutical composition | |
US9114164B2 (en) | Compositions comprising salbutamol sulphate | |
AU2016364005B2 (en) | Pharmaceutical composition | |
GB2554092A (en) | Pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: MEXICHEM AMANCO HOLDING S.A. DE C.V., MEXICO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CORR, STUART;NOAKES, TIMOTHY JAMES;SIGNING DATES FROM 20160323 TO 20160326;REEL/FRAME:052068/0782 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |